Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

@article{Logunov2020SafetyAI,
  title={Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia},
  author={D. Logunov and I. Dolzhikova and O. Zubkova and A. Tukhvatulin and D. Shcheblyakov and A. Dzharullaeva and D. M. Grousova and A. Erokhova and A. V. Kovyrshina and A. G. Botikov and F. M. Izhaeva and O. Popova and T. A. Ozharovskaya and I. Esmagambetov and I. Favorskaya and D. I. Zrelkin and D. V. Voronina and D. Shcherbinin and A. S. Semikhin and Y. Simakova and E. A. Tokarskaya and N. L. Lubenets and D. Egorova and Maksim M Shmarov and N. Nikitenko and L. Morozova and E. Smolyarchuk and Evgeny V Kryukov and V. F. Babira and S. Borisevich and B. Naroditsky and A. Gintsburg},
  journal={Lancet (London, England)},
  year={2020},
  volume={396},
  pages={887 - 897}
}
Background We developed a heterologous COVID-19 vaccine consisting of two components, a recombinant adenovirus type 26 (rAd26) vector and a recombinant adenovirus type 5 (rAd5) vector, both carrying the gene for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (rAd26-S and rAd5-S). We aimed to assess the safety and immunogenicity of two formulations (frozen and lyophilised) of this vaccine. Methods We did two open, non-randomised phase 1/2 studies at two… Expand

Figures and Tables from this paper

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
TLDR
This interim analysis of the phase 3 trial of Gam-COVID-Vac showed 91·6% efficacy against COVID-19 and was well tolerated in a large cohort. Expand
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials
TLDR
A protein subunit vaccine against COVID-19 using a dimeric form of the receptor-binding domain of the SARS-CoV-2 spike protein as the antigen is developed, ZF2001, to assess the safety and immunogenicity of this vaccine and determine the appropriate dose and schedule for an efficacy study. Expand
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: pooled analysis of two randomized, double-blind, placebo-controlled, phase 1 and 2 trials
TLDR
The safety and immunogenicity data from phase 1 and 2 trials for ZF2001 support the use of 25 g vaccine dose with three-dose schedule to an ongoing phase 3 large-scale evaluation for safety and efficacy. Expand
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
TLDR
It is demonstrated that a booster dose of ChAdOx1 nCoV-19 is safe and better tolerated than priming doses, and anti-spike neutralizing antibody titers, as well as Fc-mediated functional antibody responses, including antibody-dependent neutrophil/monocyte phagocytosis, complement activation and natural killer cell activation, are substantially enhanced by a booster doses of vaccine. Expand
Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report
TLDR
Interim findings of a controlled, randomised, double-blind trial on the immunogenicity and safety of BBV152, 3{ micro} and 6{micro} with Algel-IMDG suggest that the safety profile of this vaccine is noticeably lower than the rates for other SARS-CoV-2 vaccine platform candidates. Expand
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
TLDR
The specific objectives of this report were to assess the safety and humoral and cellular immunogenicity of a single-dose and two-dose schedule in adults older than 55 years, and safety, as measured by the occurrence of serious adverse events. Expand
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
  • Xinxue Liu, Robert H Shaw, +86 authors Lauren Allen
  • Medicine
  • The Lancet
  • 2021
TLDR
The primary endpoint was the geometric mean ratio (GMR) of serum SARS-CoV-2 anti-spike IgG concentration at 28 days after boost, which was considered non-inferior to the approved homologous schedules if the lower limit of the one-sided 97·5% CI of the GMR of these comparisons was greater than 0·63. Expand
Heterologous prime-boost immunization with CoronaVac and Convidecia
  • J. Li, L. Hou, +16 authors F. Zhu
  • Medicine
  • medRxiv
  • 2021
Background The safety and immunogenicity of heterologous prime-boost COVID-19 vaccine regimens with one shot of a recombinant adenovirus type-5-vectored COVID-19 vaccine Convidecia has not beenExpand
Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan
Background A new inactivated whole-virion QazCovid-in® vaccine against COVID-19 was developed from SARS-CoV-2 isolated in Kazakhstan, inactivated by formaldehyde, and adjuvanted with aluminiumExpand
Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates
  • S. Luo, Panli Zhang, +13 authors Chengyao Li
  • Medicine
  • Emerging microbes & infections
  • 2021
TLDR
It was concluded that prime-boost immunization with Sad23L-nCoV-S and Ad49L- nCoV -S can safely elicit strong immunity in animals in preparation of clinical phase 1/2 trials. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 40 REFERENCES
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
TLDR
A dose-escalation, single-centre, open-label, non-randomised, phase 1 trial of an Ad5 vectored COVID-19 vaccine expressing the spike glycoprotein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain to assess the safety, tolerability, and immunogenicity. Expand
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
TLDR
The first randomised controlled trial for assessment of the immunogenicity and safety of a candidate non-replicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine, aiming to determine an appropriate dose of the candidate vaccine for an efficacy study, induced significant immune responses in the majority of recipients after a single immunisation. Expand
Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia
TLDR
The data indicate that the vaccine is safe and induces strong humoral and cellular immune response in up to 100 % of healthy adult volunteers, and provide a rationale for testing efficacy in Phase III trials. Expand
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
TLDR
The mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified, which support further development of this vaccine. Expand
A heterologous virus-vectored vaccine for prevention of Middle East respiratory syndrome induces long protective immune response against MERS-CoV
TLDR
The present research showed that vaccination of animals with BVRS-GamVac-Combi induced robust humoral immune response, which persisted at least 18 months after immunization, and protected 100 % of animals from lethal infection for at least 7 months after Immunization. Expand
Immunoinformatic Analysis of T- and B-Cell Epitopes for SARS-CoV-2 Vaccine Design
TLDR
The structure-based immunoinformatic analysis for the SARS-CoV-2 S protein in this study may improve vaccine design, diagnosis, and immunotherapy against the pandemic of COVID-19. Expand
Virus-Vectored Ebola Vaccines
TLDR
This review focuses on virus-vectored Ebola vaccines that have demonstrated the greatest efficacy in preclinical trials and are currently under different phases of clinical trial, and the key vaccine parameters necessary for inducing long-term protective immunity against EVD. Expand
Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens
TLDR
This review focuses on the application of adenoviral-vectored vaccines in mucosal immunization strategies against mucosal pathogens including Mycobacterium tuberculosis, flu virus, and human immunodeficiency virus. Expand
Adenoviruses as vaccine vectors
TLDR
The molecular biology of adenoviruses as well as ways the adanovirus vectors can be manipulated to enhance their efficacy as vaccine carriers are described and methods of evaluating immune responses to transgene products expressed byadenoviral vectors are described. Expand
Consensus summary report for CEPI/BC March 12–13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines
TLDR
A scientific working meeting of experts in the field of vaccine immunology and coronaviruses was convened to consider what vaccine designs could reduce safety concerns and how animal models and immunological assessments in early clinical trials can help to assess the risk. Expand
...
1
2
3
4
...